On March 7, 2023, Carisma Therapeutics, Inc. closed the transaction.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.485 USD | +0.34% | -6.58% | -49.15% |
05-09 | Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-02 | Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
40.64 CNY | -0.25% | +1.35% | 4.61B | ||
1.485 USD | +0.34% | -6.58% | 61.48M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.15% | 61.48M | |
+5.15% | 109B | |
+11.65% | 105B | |
-0.06% | 22.25B | |
-12.18% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.79% | 16.85B | |
+4.80% | 13.76B | |
+35.30% | 12.46B |
- Stock Market
- Equities
- CARM Stock
- News Carisma Therapeutics, Inc.
- Carisma Therapeutics, Inc. announced that it has received $30 million in funding from a group of investors